Successful rituximab-CHOP treatment of systemic lupus erythematosus associated with diffuse large B-cell non-Hodgkin lymphoma

被引:9
作者
Simon, Zs. [1 ]
Tarr, T. [1 ]
Ress, Zs. [1 ]
Gergely, L. [1 ]
Kiss, E. [1 ]
Illes, A. [1 ]
机构
[1] Univ Debrecen, Dept Internal Med 3, H-4004 Debrecen, Hungary
关键词
lupus; biological therapy; non-Hodgkin lymphoma; DLBCL; rituximab;
D O I
10.1007/s00296-007-0400-z
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The authors discuss the case of a 76-year-old female patient who has been suffering from subacute cutaneous lupus erythematosus since 1983. In 1999 she was diagnosed with systemic lupus erythematosus (SLE) based on her symptoms of malar rash, polyarthritis, leukopenia, autoimmune hemolytic anemia and positive anti-DNA antibody test. For this she received methylprednisolone and cyclophosphamide. After 3 years of remission, symptoms of cutaneous vasculitis appeared in 2004, which transitionally responded to treatment with azathioprin and methylprednisolone. Her cutaneous symptoms, however, progressed quickly along with generalized lymphadenopathy, splenomegaly and thrombocytopenia. Immunohistological evaluation of the lymph node biopsy showed diffuse large B-cell lymphoma. She developed complete remission after treatment with six-cycle R-CHOP (rituximab, and reduced doses of cyclophosphamide, vincristin, adriablastin, methylprednisolone). SLE became inactive and her symptoms of vasculitis resolved. The authors are bringing attention to one of the possible late complications of systemic lupus, and also underscoring that treatment with rituximab (+CHOP) was beneficial not only for the lymphoma but the SLE as well.
引用
收藏
页码:179 / 183
页数:5
相关论文
共 19 条
[1]   The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus [J].
Anolik, JH ;
Campbell, D ;
Felgar, RE ;
Young, F ;
Sanz, I ;
Rosenblatt, J ;
Looney, RJ .
ARTHRITIS AND RHEUMATISM, 2003, 48 (02) :455-459
[2]   An International Cohort Study of Cancer in Systemic Lupus Erythematosus [J].
Bernatsky, S ;
Boivin, JF ;
Joseph, L ;
Rajan, R ;
Zoma, A ;
Manzi, S ;
Ginzler, E ;
Urowitz, M ;
Gladman, D ;
Fortin, PR ;
Petri, M ;
Edworthy, S ;
Barr, S ;
Gordon, C ;
Bae, SC ;
Sibley, J ;
Isenberg, D ;
Rahman, A ;
Aranow, C ;
Dooley, MA ;
Steinsson, K ;
Nived, O ;
Sturfelt, G ;
Alarcón, G ;
Senécal, JL ;
Zummer, M ;
Hanly, J ;
Ensworth, S ;
Pope, J ;
El-Gabalawy, H ;
McCarthy, T ;
Pierre, YS ;
Ramsey-Goldman, R ;
Clarke, A .
ARTHRITIS AND RHEUMATISM, 2005, 52 (05) :1481-1490
[3]   Optimum therapeutic approaches for lupus nephritis: what therapy and for whom? [J].
Boumpas, DT ;
Sidiropoulos, P ;
Bertsias, G .
NATURE CLINICAL PRACTICE RHEUMATOLOGY, 2005, 1 (01) :22-30
[4]   An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab [J].
Boye, J ;
Elter, T ;
Engert, A .
ANNALS OF ONCOLOGY, 2003, 14 (04) :520-535
[5]   From the bench to the bedside: ways to improve rituximab efficacy [J].
Cartron, G ;
Watier, H ;
Golay, J ;
Solal-Celigny, P .
BLOOD, 2004, 104 (09) :2635-2642
[6]   Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene [J].
Cartron, G ;
Dacheux, L ;
Salles, G ;
Solal-Celigny, P ;
Bardos, P ;
Colombat, P ;
Watier, H .
BLOOD, 2002, 99 (03) :754-758
[7]   CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].
Coiffier, B ;
Lepage, E ;
Brière, J ;
Herbrecht, R ;
Tilly, H ;
Bouabdallah, R ;
Morel, P ;
Van den Neste, E ;
Salles, G ;
Gaulard, P ;
Reyes, F ;
Gisselbrecht, C .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242
[8]   SLE - Rituximab in lupus [J].
Eisenberg, R .
ARTHRITIS RESEARCH & THERAPY, 2003, 5 (04) :157-159
[9]  
GERGELY L, 2004, MAGY BELORV ARCH, V57, P26
[10]  
Isenberg DA, 2006, J RHEUMATOL, V33, P24